Biopharma

Astellas shifts investment focus to later-stage opportu...

In the last few years, Astellas has invested heavily in novel technologies that ...

Use of Secondary CVD Prevention Medications Low in Most...

WEDNESDAY, Feb. 12, 2025 -- Use of secondary cardiovascular disease (CVD) preven...

Acute Toxicity Following Prostate Radiotherapy Linked t...

WEDNESDAY, Feb. 12, 2025 -- For patients undergoing prostate radiotherapy, acute...

Performance of AI Preeclampsia Prediction Models Deteri...

WEDNESDAY, Feb. 12, 2025 -- For the Preeclampsia Integrated Estimate of RiSk (PI...

Overdiagnosis of Thyroid Cancer Persists

WEDNESDAY, Feb. 12, 2025 -- Overdiagnosis of thyroid cancer in the United States...

Lithium Linked to Risk for Thyroid Dysfunction, CKD in ...

WEDNESDAY, Feb. 12, 2025 -- Lithium is associated with an increased risk for thy...

Mortality Up for Individuals Who Need Hospital-Based Ca...

WEDNESDAY, Feb. 12, 2025 -- Individuals who require hospital-based care for cann...

In 2023, 1.4 Percent of U.S. Children Ever Experienced ...

WEDNESDAY, Feb. 12, 2025 -- Post-COVID condition (PCC) continues to affect chil...

Probiotics Linked to Reduced Mortality in Infants Born ...

WEDNESDAY, Feb. 12, 2025 -- For infants born before 34 weeks of gestation and wi...

Fierce Biotech Fundraising Tracker '25: Abcuro raises $...

The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 mil...

Seeking fruitful Lenmeldy launch, Orchard names commerc...

Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenm...

AstraZeneca’s Alexion creates interactive fantasy story...

To guide children through an atypical hemolytic uremic syndrome diagnosis and su...

New study offers hints of GLP-1 drugs’ potential in cur...

A small semaglutide trial suggests the medicine's suppression of appetite may ex...

UK court rules against Abbott in diabetes CGM trademark...

Abbott had claimed that Sinocare’s iCan i3 wearable CGM was too similar to its F...

STAT+: AI agents, bursting the AI drug hype bubble, and...

The web edition of STAT’s AI Prognosis newsletter, our subscriber-exclusive guid...

Biogen CEO hails quartet of new launches as multiple sc...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-...

GSK plans to move vaccine R&D group from Maryland to th...

After calling Rockville, Maryland, home for more than eight years, GSK's vaccine...

Biogen inks royalty deal to gain funding for lupus drug...

The agreement hands Biogen as much as $250 million in exchange for milestone pay...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Skytrofa (previously L...

AnaptysBio’s PD-1 drug reduces rheumatoid arthritis in ...

AnaptysBio may have ended last year on a low, but 2025 is looking up with the ne...

Regulatory tracker: Bayer, BridgeBio's ATTR drug wins a...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Actelsar HCT, telmisar...

Trump orders agencies to plan for ‘large-scale’ job cuts

While Trump’s executive order provides substantial power to Elon Musk’s DOGE eff...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Copalia HCT, amlodipin...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.